AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Research
The volume and pace of cancer research, from preclinical studies to clinical trials and FDA approvals, can make it challenging to stay informed. This section highlights the latest developments and translates complex scientific concepts into clear, accessible insights for both healthcare professionals and the broader public.
Multiple Myeloma and Plasma Cell Disorders in 2026: Bispecifics Move Earlier, MRD Guides Duration, and Amyloidosis Finally Has a Target
By Laahn Foster, MD
The data presented at ASCO 2026 provide more clarity on where bispecifics fit in the treatment sequence, how long to use them, and whether they can be used as an earlier intervention.
Multiple Myeloma and Plasma Cell Disorders in 2026: Bispecifics Move Earlier, MRD Guides Duration, and Amyloidosis Finally Has a Target
By Laahn Foster, MD
The data presented at ASCO 2026 provide more clarity on where bispecifics fit in the treatment sequence, how long to use them, and whether they can be used as an earlier intervention.
Multiple Myeloma and Plasma Cell Disorders in 2026: Bispecifics Move Earlier, MRD Guides Duration, and Amyloidosis Finally Has a Target
By Laahn Foster, MD
The data presented at ASCO 2026 provide more clarity on where bispecifics fit in the treatment sequence, how long to use them, and whether they can be used as an earlier intervention.
Relapsed and Refractory DLBCL in 2026: More Options Than Ever, and Three Questions That Actually Matter
By Timothy Fenske, MD
Four of the five randomized R/R DLBCL trials showing overall survival benefit have come in the last four years. Dr. Timothy Fenske maps the 2026 options and the three questions that actually guide treatment selection.
Relapsed and Refractory DLBCL in 2026: More Options Than Ever, and Three Questions That Actually Matter
By Timothy Fenske, MD
Four of the five randomized R/R DLBCL trials showing overall survival benefit have come in the last four years. Dr. Timothy Fenske maps the 2026 options and the three questions that actually guide treatment selection.
Relapsed and Refractory DLBCL in 2026: More Options Than Ever, and Three Questions That Actually Matter
By Timothy Fenske, MD
Four of the five randomized R/R DLBCL trials showing overall survival benefit have come in the last four years. Dr. Timothy Fenske maps the 2026 options and the three questions that actually guide treatment selection.
Next-Generation KRAS Inhibitors in NSCLC: A Pipeline So Active It's Hard to Keep Up
By Robert Chun-Hao Hsu, MD
KRAS was considered undruggable for decades. The protein's smooth, shallow surface offered no obvious pocket for small molecule binding. Its extremely high affinity for GTP/GDP made competitive inhibition impractical.
Next-Generation KRAS Inhibitors in NSCLC: A Pipeline So Active It's Hard to Keep Up
By Robert Chun-Hao Hsu, MD
KRAS was considered undruggable for decades. The protein's smooth, shallow surface offered no obvious pocket for small molecule binding. Its extremely high affinity for GTP/GDP made competitive inhibition impractical.
Next-Generation KRAS Inhibitors in NSCLC: A Pipeline So Active It's Hard to Keep Up
By Robert Chun-Hao Hsu, MD
KRAS was considered undruggable for decades. The protein's smooth, shallow surface offered no obvious pocket for small molecule binding. Its extremely high affinity for GTP/GDP made competitive inhibition impractical.
Daraxonrasib and the RASolute 302 Trial: A Paradigm Shift in the RAS Targeting Era and Management of Pancreatic Cancer
By Meghana Singh, MD; Ibrahim Halil Sahin, MD
For the first time, a targeted therapy has doubled overall survival in second-line metastatic pancreatic cancer. Two oncologists break down the RASolute 302 trial and what daraxonrasib means for the field.
Daraxonrasib and the RASolute 302 Trial: A Paradigm Shift in the RAS Targeting Era and Management of Pancreatic Cancer
By Meghana Singh, MD; Ibrahim Halil Sahin, MD
For the first time, a targeted therapy has doubled overall survival in second-line metastatic pancreatic cancer. Two oncologists break down the RASolute 302 trial and what daraxonrasib means for the field.
Daraxonrasib and the RASolute 302 Trial: A Paradigm Shift in the RAS Targeting Era and Management of Pancreatic Cancer
By Meghana Singh, MD; Ibrahim Halil Sahin, MD
For the first time, a targeted therapy has doubled overall survival in second-line metastatic pancreatic cancer. Two oncologists break down the RASolute 302 trial and what daraxonrasib means for the field.
Small Cell Lung Cancer in 2026: A Field That Has Finally Started Moving
By Deepti Behl, MD
Platinum-etoposide served as the cornerstone of therapy, producing rapid responses that were often followed by equally rapid relapses, and few effective subsequent options.
Small Cell Lung Cancer in 2026: A Field That Has Finally Started Moving
By Deepti Behl, MD
Platinum-etoposide served as the cornerstone of therapy, producing rapid responses that were often followed by equally rapid relapses, and few effective subsequent options.
Small Cell Lung Cancer in 2026: A Field That Has Finally Started Moving
By Deepti Behl, MD
Platinum-etoposide served as the cornerstone of therapy, producing rapid responses that were often followed by equally rapid relapses, and few effective subsequent options.
Peripheral T-Cell Lymphoma in 2026: Reclassification, BV-CHP as Standard, and a Pipeline Finally Targeting Disease Biology
By Ranjit Nair, MD
Peripheral T-cell lymphomas are among the most challenging malignancies in hematologic oncology.
Peripheral T-Cell Lymphoma in 2026: Reclassification, BV-CHP as Standard, and a Pipeline Finally Targeting Disease Biology
By Ranjit Nair, MD
Peripheral T-cell lymphomas are among the most challenging malignancies in hematologic oncology.
Peripheral T-Cell Lymphoma in 2026: Reclassification, BV-CHP as Standard, and a Pipeline Finally Targeting Disease Biology
By Ranjit Nair, MD
Peripheral T-cell lymphomas are among the most challenging malignancies in hematologic oncology.
Multiple Myeloma in 2026: Redefining the Possible — From Three-Year Median Survival to the Threshold of Cure
By Shaji K. Kumar, MD
Median survival in multiple myeloma has grown from three years to potentially fifteen. Dr. Shaji Kumar maps the 2026 treatment landscape — from quadruplet induction to immunotherapy in first relapse and the threshold of cure.
Multiple Myeloma in 2026: Redefining the Possible — From Three-Year Median Survival to the Threshold of Cure
By Shaji K. Kumar, MD
Median survival in multiple myeloma has grown from three years to potentially fifteen. Dr. Shaji Kumar maps the 2026 treatment landscape — from quadruplet induction to immunotherapy in first relapse and the threshold of cure.
Multiple Myeloma in 2026: Redefining the Possible — From Three-Year Median Survival to the Threshold of Cure
By Shaji K. Kumar, MD
Median survival in multiple myeloma has grown from three years to potentially fifteen. Dr. Shaji Kumar maps the 2026 treatment landscape — from quadruplet induction to immunotherapy in first relapse and the threshold of cure.
ASCO 2026: Sima Ehsani Chimeh, MD, on the VIKTORIA-1 Trial in HR+/HER2-Negative Advanced Breast Cancer
By The Cancer News Team
VIKTORIA-1 data show gedatolisib roughly doubled PFS versus alpelisib in PIK3CA-mutant HR+/HER2-negative advanced breast cancer — with a more favorable tolerability profile. An expert breaks down the findings.
ASCO 2026: Sima Ehsani Chimeh, MD, on the VIKTORIA-1 Trial in HR+/HER2-Negative Advanced Breast Cancer
By The Cancer News Team
VIKTORIA-1 data show gedatolisib roughly doubled PFS versus alpelisib in PIK3CA-mutant HR+/HER2-negative advanced breast cancer — with a more favorable tolerability profile. An expert breaks down the findings.
ASCO 2026: Sima Ehsani Chimeh, MD, on the VIKTORIA-1 Trial in HR+/HER2-Negative Advanced Breast Cancer
By The Cancer News Team
VIKTORIA-1 data show gedatolisib roughly doubled PFS versus alpelisib in PIK3CA-mutant HR+/HER2-negative advanced breast cancer — with a more favorable tolerability profile. An expert breaks down the findings.
Bispecific Antibodies and Fixed-Duration CLL Therapy: The Lymphoma and CLL Landscape in 2026
By Jennifer Huang, PhD, MD
The 2026 lymphoma and CLL landscape is defined by maturing long-term data, the shift of bispecific antibodies into earlier treatment lines, and the emergence of all-oral, fixed-duration regimens.
Bispecific Antibodies and Fixed-Duration CLL Therapy: The Lymphoma and CLL Landscape in 2026
By Jennifer Huang, PhD, MD
The 2026 lymphoma and CLL landscape is defined by maturing long-term data, the shift of bispecific antibodies into earlier treatment lines, and the emergence of all-oral, fixed-duration regimens.
Bispecific Antibodies and Fixed-Duration CLL Therapy: The Lymphoma and CLL Landscape in 2026
By Jennifer Huang, PhD, MD
The 2026 lymphoma and CLL landscape is defined by maturing long-term data, the shift of bispecific antibodies into earlier treatment lines, and the emergence of all-oral, fixed-duration regimens.
Early-Stage Lung Cancer in 2026: Why Detection Still Changes Everything
By Thomas Templin, MD MBA
Lung cancer remains the world’s leading cause of cancer death. Reducing tobacco use has helped, but it has not solved the problem.
Early-Stage Lung Cancer in 2026: Why Detection Still Changes Everything
By Thomas Templin, MD MBA
Lung cancer remains the world’s leading cause of cancer death. Reducing tobacco use has helped, but it has not solved the problem.
Early-Stage Lung Cancer in 2026: Why Detection Still Changes Everything
By Thomas Templin, MD MBA
Lung cancer remains the world’s leading cause of cancer death. Reducing tobacco use has helped, but it has not solved the problem.